AVTR Stock Recent News

Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline.

Avantor, Inc. AVTR reported better-than-expected second-quarter earnings results on Friday.

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.

Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% Net income of $93 million; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. , July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024.

NEW YORK , July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.

Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Avantor, Inc. AVTR recently released two innovative products aimed at revolutionizing the gene therapy harvest process. J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease are designed to enhance efficiency, reduce environmental impact, improve operational outcomes and preserve the integrity of viral particles.

Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.

RADNOR, Pa. , June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m.